Argenx to Participate in Two Major Investor Conferences in the US this June
Belgian biotech company Argenx announced on Wednesday its participation in two major investor conferences in the United States in June. Members of its management will present the group's strategy and activities, specializing in immunology.
Argenx will participate in the William Blair 46th Annual Growth Stock Conference, with a presentation scheduled for Wednesday, June 3 at 12:40 PM Central Time in Chicago. The company will also be represented at the Goldman Sachs 47th Annual Global Healthcare Conference by a fireside chat on Tuesday, June 9 at 4:00 PM Eastern Time in Miami. The presentations will be available live via a webcast from the Investors section of the argenx.com/investors website. A replay will remain available on the website for about 30 days following each presentation.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1.3MD€
Net income: 366M€
Guidance from the release
argenx continue de livrer un impact significatif pour les patients.
Argentx affiche une croissance de 63% par rapport à l'année précédente.
Risks mentioned
Les résultats peuvent varier en fonction des incertitudes liées aux essais cliniques.
L'impact des lois et règlements gouvernementaux pourrait affecter les activités.
Opportunities identified
VYVGART pourrait devenir la première thérapie approuvée dans les populations gMG.
Lancement d'une étude pour le candidat pipeline empasiprubart.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
